Key Takeaways:
- SAG’s LiquidMate O helps pharmaceutical companies and hospitals improve item-level tracking, inventory accuracy, DSCSA compliance, and patient safety.
- The direct-on-vial UHF RFID label uses a patent-pending antenna design to deliver reliable reads across liquid-filled injectable medications.
RFID tagging challenge enabler SAG has rolled out LiquidMate O, its debut UHF RFID label for pharmaceutical RFID and item-level traceability.
Built on a patent-pending antenna architecture, LiquidMate O delivers reliable direct-on-vial RFID tagging for liquid-filled injectable medications, an application long considered one of the most technically challenging in RFID deployment. Ineffective tracking of injectable drugs continues to drive substantial losses through expired inventory, misplaced medications, and regulatory exposure—particularly for high-value or critical products.
As enforcement of the U.S. Drug Supply Chain Security Act (DSCSA) accelerates, dependable, high-accuracy RFID-based medication tracking has become essential to both pharmaceutical manufacturing and hospital operations, said SAG officials.
What SAG offers for RFID Labelers
Terry Chiang, CEO of SAG, noted the company offers more than two decades of experience supporting healthcare and industrial RFID applications.
“We have seen how reliability at the item level directly impacts compliance, efficiency, and patient safety,” said Chiang in a statement. “LiquidMate O reflects our focus on solving the most technically complex tagging challenges in healthcare and delivering scalable, standards-based traceability solutions that pharmaceutical organizations can deploy with confidence.”
Details on LiquidMate O
Through deep expertise in tailored antenna design, materials science, and self-developed manufacturing systems, SAG delivers reliable RFID connectivity that performs under demanding operational and environmental constraints—enabling organizations to address complex, mission-critical workflow challenges through advanced RFID solutions, according to company officials.
LiquidMate O is purpose-built to enable scalable, item-level tracking across a broad range of injectable liquid categories that have historically constrained direct-on-vial RFID adoption. Its performance has been independently validated through AXIA Lab–defined test scenarios, using representative liquid formulations and workflow conditions aligned with real clinical practice, said Chiang.
Conventional direct-on-vial solutions often suffer from inconsistent performance on liquid-filled injectables due to dielectric effects, while flag-style labels, although RF-robust, pose handling, automation, and scalability challenges that limit broader adoption. LiquidMate O eliminates this trade-off by delivering a true direct-on-vial RFID solution with consistent performance across diverse injectable formulations. Key capabilities include:
- One label across multiple formulations. Consistent RFID performance across injectable liquids with varying dielectric properties, eliminating formulation-specific labels and significantly reducing SKU complexity.
- True direct-on-vial design. Validated on industry-standard 10 mL glass vials with a compact 62 × 20 mm label engineered for curved, space-constrained pharmaceutical packaging.
- Proven high-density readability. Independently validated by AXIA Lab, achieving 100% read performance in dense, multi-vial configurations with full 360-degree.
By reducing manual scanning steps and minimizing SKU proliferation, LiquidMate O supports real-time inventory visibility, accurate dispensing, and enhanced patient safety without disrupting existing packaging lines.